Effects of SCN2A Gene Polymorphism on Drug Response in Han Chinese Children with Epilepsy

Area of Science:

• Genetics
• Neurology
• Pharmacogenomics

Background:

• Childhood epilepsy is a common neurological disorder affecting child development.
• Treatment efficacy for epilepsy varies, and genetic factors may play a role.
• The sodium voltage-gated channel alpha subunit 2 gene (SCN2A) is implicated in neurological function.

Purpose of the Study:

• To investigate the impact of SCN2A gene polymorphisms (rs2121371 and rs1864885) on epilepsy drug efficacy.
• To explore the association between these SCN2A polymorphisms and adverse drug reactions, including liver injury.

Main Methods:

• Genotyping of SCN2A rs2121371 and rs1864885 in 98 pediatric epilepsy patients using polymerase chain reaction.
• Classification of patients into seizure-free and epileptic-seizure groups based on drug response.
• Categorization of patients based on the presence or absence of drug-induced liver injury.
• Logistic regression analysis to determine correlations between polymorphisms and clinical outcomes.

Main Results:

• Significant differences in allele frequencies for rs2121371 and rs1864885 were observed between seizure groups.
• The C allele and CC genotype of rs2121371 were associated with adverse drug reactions (P = 0.004, P = 0.013).
• The G allele and AG genotype of rs1864885 were linked to adverse drug reactions (P < 0.001).
• rs2121371 polymorphism correlated with drug-induced liver injury, while rs1864885 did not show this association.

Conclusions:

• SCN2A gene polymorphisms rs2121371 and rs1864885 may influence the efficacy of epilepsy treatments in children.
• These SCN2A variants are associated with adverse drug reactions and, for rs2121371, with liver injury.
• Findings suggest potential for SCN2A genotyping in personalized epilepsy treatment strategies.